Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies
- Author
- FRYAR-TITA, Elizabeth B1 ; DAS, Jharna R2 ; DAVIS, J. H3 ; DESOTO, J. A4 ; GREEN, Sidney2 ; SOUTHERLAND, William M5 ; BOWEN, Donnell2
[1] Department of Environmental Sciences and Engineering, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
[2] Department of Pharmacology, College of Medicine, Howard University, Washington, DC, United States
[3] Pharmacy School, Hampton University, Hampton VA, United States
[4] National Institutes of Health, NIDDK, Bethesda MD, United States
[5] Department of Biochemistry, College of Medicine, Howard University, Washington, DC, United States - Source
Anticancer research. 2007, Vol 27, Num 3B, pp 1393-1399, 7 p ; ref : 17 ref
- ISSN
- 0250-7005
- Scientific domain
- Medical oncology
- Publisher
- International Institute of Anticancer Research, Attiki
- Publication country
- Greece
- Document type
- Article
- Language
- English
- Author keyword
- 5-fluorouracil Selective estrogen receptor modulator breast cancer osteoporosis raloxifene trimetrexate
- Keyword (fr)
- Anticancéreux Cancérologie Cycle cellulaire Fluorouracil Ostéoporose Raloxifène Traitement Trimétrexate Cancer du sein Modulateur sélectif récepteur oestrogène Agoniste antagoniste Antifolate Antihormone Antimétabolite Antioestrogène Benzothiophène dérivé Composé non stéroïde Dihydrofolate reductase Enzyme Fluoropyrimidine dérivé Glande mammaire pathologie Inhibiteur enzyme Methyltransferases Oxidoreductases Pyrimidine dérivé Récepteur oestrogène Système ostéoarticulaire pathologie Thymidylate synthase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Cancerology Cell cycle Fluorouracil Osteoporosis Raloxifene Treatment Trimetrexate Breast cancer Selective estrogen receptor modulator Agonist antagonist Antifolate Antihormone Antimetabolic Antiestrogen Benzothiophene derivatives Non steroid compound Dihydrofolate reductase Enzyme Fluoropyrimidine derivatives Mammary gland diseases Enzyme inhibitor Methyltransferases Oxidoreductases Pyrimidine derivatives Estrogen receptor Diseases of the osteoarticular system Thymidylate synthase Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cancerología Ciclo celular Fluorouracilo Osteoporosis Raloxifeno Tratamiento Trimetrexato Cáncer de pecho Agonista antagonista Antifolato Antihormona Antimetabólito Antiestrógeno Benzotiofeno derivado Compuesto no esteroide Dihydrofolate reductase Enzima Fluoropirimidina derivado Glándula mamaria patología Inhibidor enzima Methyltransferases Oxidoreductases Pirimidina derivado Receptor estrógeno Sistema osteoarticular patología Thymidylate synthase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18853766
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"3B\";s:8:\"\u0000*\u0000spage\";s:4:\"1393\";s:8:\"\u0000*\u0000epage\";s:4:\"1399\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FRYAR-TITA\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Elizabeth B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"DAS, Jharna R\";i:1;s:11:\"DAVIS, J. H\";i:2;s:12:\"DESOTO, J. A\";i:3;s:13:\"GREEN, Sidney\";i:4;s:22:\"SOUTHERLAND, William M\";i:5;s:14:\"BOWEN, Donnell\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"3B\";s:8:\"\u0000*\u0000spage\";s:4:\"1393\";s:8:\"\u0000*\u0000epage\";s:4:\"1399\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FRYAR-TITA\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Elizabeth B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"DAS, Jharna R\";i:1;s:11:\"DAVIS, J. H\";i:2;s:12:\"DESOTO, J. A\";i:3;s:13:\"GREEN, Sidney\";i:4;s:22:\"SOUTHERLAND, William M\";i:5;s:14:\"BOWEN, Donnell\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"3B\";s:8:\"\u0000*\u0000spage\";s:4:\"1393\";s:8:\"\u0000*\u0000epage\";s:4:\"1399\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FRYAR-TITA\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Elizabeth B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"DAS, Jharna R\";i:1;s:11:\"DAVIS, J. H\";i:2;s:12:\"DESOTO, J. A\";i:3;s:13:\"GREEN, Sidney\";i:4;s:22:\"SOUTHERLAND, William M\";i:5;s:14:\"BOWEN, Donnell\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"3B\";s:8:\"\u0000*\u0000spage\";s:4:\"1393\";s:8:\"\u0000*\u0000epage\";s:4:\"1399\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FRYAR-TITA\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Elizabeth B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"DAS, Jharna R\";i:1;s:11:\"DAVIS, J. H\";i:2;s:12:\"DESOTO, J. A\";i:3;s:13:\"GREEN, Sidney\";i:4;s:22:\"SOUTHERLAND, William M\";i:5;s:14:\"BOWEN, Donnell\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Anticancer research\";s:9:\"\u0000*\u0000stitle\";s:14:\"Anticancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"3B\";s:8:\"\u0000*\u0000spage\";s:4:\"1393\";s:8:\"\u0000*\u0000epage\";s:4:\"1399\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0250-7005\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"FRYAR-TITA\";s:10:\"\u0000*\u0000aufirst\";s:11:\"Elizabeth B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"DAS, Jharna R\";i:1;s:11:\"DAVIS, J. H\";i:2;s:12:\"DESOTO, J. A\";i:3;s:13:\"GREEN, Sidney\";i:4;s:22:\"SOUTHERLAND, William M\";i:5;s:14:\"BOWEN, Donnell\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Raloxifene and selective cell cycle specific agents : A case for the inclusion of raloxifene in current breast cancer treatment therapies\";s:8:\"\u0000*\u0000place\";s:6:\"Attiki\";s:6:\"\u0000*\u0000pub\";s:46:\"International Institute of Anticancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
